Could a new approach for treating lupus be under way?

An antibiotic or vaccine aimed at a gut bacterium suppresses lupus-like autoimmunity in mice

Categories: For Potential Participants, [Lupus, Lupus cause, Lupus vaccine, New lupus research]

Our intestine is colonized by a vast number of microbes, collectively referred to as the human microbiota. The microbiota is part of the gut barrier and helps our bodies by:

  • regulating the immune system
  • strengthening the gut
  • helping to digest food
  • protecting against infections.

An abnormal microbiota may affect our body by allowing foreign substances to leak from the gut into other parts of the body. There is some evidence that this, in turn, may initiate both local and systemic immune responses causing various diseases, including systemic lupus erythematosus.

A recent study at Yale University suggests that Enterococcus gallinarum, a bacterium found in the small intestines of humans and mice, can travel to other parts of the body such as the spleen, liver, and lymph nodes. The researchers discovered that, while invading other tissues, the bacterium can stir up lupus-like autoimmune problems. The findings were made in mice prone to developing an autoimmune disease because of their genetic makeup. The discoveries were later supported by observations in liver cells removed from healthy people and studied in a laboratory. This suggests that similar inflammatory processes to those in mice may take place in humans with a predisposition to autoimmune diseases.

Further investigations showed that the autoimmune response in mice can be suppressed by specifically targeting Enterococcus gallinarum with an antibiotic or vaccine. By using either approach, the Yale team were able to reverse the effect of this bacterium on the immune system. Interestingly, the use of a vaccine against other types of bacteria did not stop autoimmunity or prevent mortality.

What’s next

Although further research needs to be done, these findings suggest that this bacterium may be relevant to autoimmune diseases and, more specifically, to serious conditions like autoimmune liver disease and systemic lupus erythematosus. This observation has also paved the way for future studies looking at whether the use of antibiotics and vaccines could benefit patients with autoimmune diseases.

Keep up to date on the latest research

Interested in learning more about lupus? Register on to receive news about lupus and related IQVIA clinical trials. Check often for updates and news on a variety of disease areas and to find out more about some of the latest clinical research trials.


Want more information about clinical trials near you?

Register to get notifications about clinical trials in your area.
Register to Receive Updates